| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10092009 | The Journal of Pediatrics | 2005 | 5 Pages |
Abstract
Rituximab may be a useful treatment for chronic immune thrombocytopenic purpura in children with a >50% CR rate lasting an average of 13 months, with 9 of 15 CRs ongoing (8 lasted 6 months or longer). There was no substantial toxicity other than transient serum sickness.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
Julie MD, Joseph M. MD, Ruth MD, Jay MD, Michael A. BA, James B. MD,